Electrochemical determination of xanthine oxidase inhibitor drug in urate lowering therapy using graphene nanosheets modified electrode

被引：0
作者：
机构：
[1] Centre for Nanoscience and Nanotechnology, Department of Chemistry, Gandhigram Rural Institute, Gandhigram 624 302, Dindigul, Tamilnadu
来源：
John, S.A. (abrajohn@yahoo.co.in) | 1600年 / Elsevier Ltd卷 / 117期
关键词：
Allopurinol; Amperometry; Electrochemically reduced graphene oxide; Human blood serum and urine samples; XPS;
D O I：
10.1016/j.electacta.2013.11.170
中图分类号：
学科分类号：
摘要：
We report the electrochemical determination of urate lowering therapeutic drug, allopurinol (AP) using the electrochemically reduced graphene oxide (ERGO) modified glassy carbon electrode (GCE). The ERGO modified GCE was fabricated by self-assembling graphene oxide (GO) on 1,6-hexadiamine (HDA) modified GCE by the electrostatic interaction between the positively charged amine group and the negatively charged GO layers followed by the electrochemical reduction of GO layers at negative potential. XPS results confirmed the attachment of GO and its electrochemical reduction. The electrochemical behavior of AP was examined at ERGO modified electrode in the presence of ascorbic acid (AA) and uric acid (UA). It was found that ERGO modified electrode not only enhanced the oxidation currents of AP, AA and UA but also showed stable signals for them for repetitive potential cycles. The present modified electrode was successfully used to determine these analytes simultaneously in a mixture. Selective determination of AP in the presence of high concentrations of AA and UA was also demonstrated at ERGO modified GCE. Using amperometry, detections of 40 and 200 nM of UA and AP were achieved and the detection limits were found to be 9.0 × 10 -9 M and 1.1 × 10-7 M, respectively (S/N = 3). Further, the practical application of the present modified electrode was demonstrated by simultaneously determining the concentrations of AA, UA and AP in human blood serum and urine samples. © 2013 Elsevier Ltd.
引用
收藏
页码：360 / 366
页数：6
相关论文
共 37 条
  • [1] Pacher P., Nivorozhkin A., Szabo C., Therapeutic effects of xanthine oxidase inhibitors: Renaissance half a century after the discovery of allopurinol, Pharm. Rev., 58, (2006)
  • [2] Rundles R.W., Wyngaarden J.B.B., Drugs and uric acid, Annu. Rev. Pharmacol., 9, (1969)
  • [3] Kim K.Y., Schumacher H.R., Hunsche E., Wertheimer A.I., Kong S.X., A literature review of the epidemiology and treatment of acute gout, Clin. Ther., 25, (2003)
  • [4] Watts R.W., Snedden W., Parker R.A., A quantitative study of skeletal-muscle purines and pyrazolo(3,4-d) pyrimidines in gout patients treated with allopurinol, Clin. Sci., 41, (1971)
  • [5] Hille R., George G.N., Eidsness M.K., Cramer S.P., EXAFS analysis of xanthine oxidase complexes with alloxanthine, violapterin, and 6-pteridylaldehyde, Inorg. Chem., 28, (1989)
  • [6] Taylor M.D., Mellert T.K., Parmentier J.I., Eddy L.J., Pharmacological protection of reoxygenation damage to in vitro brain slice tissue, Brain Res., 347, (1985)
  • [7] Suzuki Y., Sudo J., Tanabe T., Allopurinol toxicity: Its toxic organ-specificity between the liver and the kidney in the rat, J. Toxicol. Sci., 9, (1984)
  • [8] Keough D.T., Hockova D., Holy A., Naesens L.M.J., Skinner-Adams T.S., De Jersey J., Guddat L.W., Inhibition of hypoxanthine-guanine phosphoribosyltransferase by acyclic nucleoside phosphonates: A new class of antimalarial therapeutics, J. Med. Chem., 52, (2009)
  • [9] Biagi G., Costantini A., Costantino L., Giorgi I., Livi O., Pecorari P., Rinaldi M., Scartoni V., Synthesis and biological evaluation of new imidazole, pyrimidine, and purine derivatives and analogs as inhibitors of xanthine oxidase, J. Med. Chem., 39, (1996)
  • [10] Murali R., Drug Index, (1998)
1234